HOME >> BIOLOGY >> NEWS
CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell

SAN ANTONIO -- The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. CTRC is one of only three sites in the United States, and the only in Texas, enrolling patients. The novel anti-cancer therapy, REOLYSIN, is a living virus, not a chemotherapy drug, that is toxic to cancer cells but not harmful to normal cells. This novel therapy, using a living virus, is the first of its kind available at CTRC. According to Monica Mita, MD, principal investigator at the CTRC Institute for Drug Development, REOLYSINs name was derived from the human reovirus, a mild virus that occurs naturally in the environment.

This novel therapy has shown success because the reovirus replicates in and destroys the cancer cells within the patients body, said Mita. Cancer cells have several molecular and genetic abnormalities. In normal, healthy cells, the reovirus is unable to reproduce because of an enzyme named PKR. The enzyme is suppressed in cancer cells, and therefore the reovirus can replicate in the cancer cell and kill it.

REOLYSIN typifies the true targeted therapy approach that seeks to use fundamental differences between cancer and normal cells as the basis for effective anti-cancer approaches and we are thus very excited about the this study, said Francis Giles, MD, director of the CTRC Institute for Drug Development.

Eligible patients are those who have a bone or soft tissue sarcoma that has spread to the lung and who are deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumors, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

The second patient to enroll in the st
'"/>

Contact: Jill. B. Byrd
jbyrd@ctrc.net
210-450-5550
Cancer Therapy & Research Center (CTRC)
24-Jul-2007


Page: 1 2

Related biology news :

1. Saudi Arabias KAUST names WHOI first research partner
2. Which came first, the moth or the cactus?
3. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
4. Seawater intrusion is the first cause of contamination of coastal aquifers
5. Camera-shy deer caught for first time
6. New joint replacement material developed at MGH put to first clinical use
7. Liverpool amongst first in UK to install unique DNA sequencing technology
8. A first-principles model of early evolution
9. Worlds first X-ray free electron laser is on course to completion
10. Scientists identify first gene linked to scoliosis
11. Which came first: Primates ability to see colorful food or see colorful sex?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/27/2019)... ... November 26, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a ... Foundation and hosted by Dr. Steven Sampson and Dr. Danielle Aufiero of the ... 23, 2019, highlighted the ongoing efforts to promote research, educate the public, and provide ...
(Date:11/22/2019)... ... November 21, 2019 , ... The inventors of ... have announced a major step forward with that therapy, known as SurVaxM. MimiVax ... company, spun off from Roswell Park in 2012, has entered into a China-exclusive ...
(Date:11/19/2019)... ... ... Project Lifeline – a community partnership and research program initiated ... use disorder (SUD) – will take center stage at the upcoming NACDS ... in preventing and treating opioid abuse in Blair County, Pennsylvania, will receive the NACDS ...
Breaking Biology News(10 mins):
(Date:10/30/2019)... ... October 30, 2019 , ... ... the many roles innovation and technology play in educating the next generation of ... hands-on learning opportunities and presentations by WesternU administrators and representatives of companies working ...
(Date:10/29/2019)... ... October 29, 2019 , ... Researchers ... Using Silios CMS-C multispectral imagers , researchers identified people by the image ... based on retinal imaging, face recognition, fingerprints and vasculature. , The new ...
(Date:10/22/2019)... ... October 22, 2019 , ... Catalent, a global leader in clinical supply services, ... Integration, will participate in a panel session titled “Cell and Gene Therapy Logistics” at ... Gwen Hotel, Chicago, on Oct. 28-30, 2019. , The panel session, on Wednesday, Oct. ...
(Date:10/17/2019)... PARK, Kan. (PRWEB) , ... October 15, 2019 ... ... to 23andMe, a leader among services that offer DNA Testing for health and/or ... so popular. Everywhere you look, it seems that people want to know more ...
Breaking Biology Technology:
Cached News: